BXQ-350 is under clinical development by Bexion Pharmaceuticals and currently in Phase II for Pediatric Diffuse Intrinsic Pontine Glioma.

Acalabrutinib is under development for the treatment of peanut food allergy, recurrent or refractory central nervous system lymphoma (CNSL), anti-MAG mediated neuropathy, multiple myeloma, hairy cell ...

Diabetic neuropathy refers to nerve damage due to diabetes. When it affects the feet, healthcare professionals call it peripheral neuropathy. It usually affects both feet at the same time ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within ...